Background: We previously reported that higher levels of mitochondrial DNA copy number (mtDNA CN) were associated with lung cancer risk among male heavy smokers (i.e., 20 cigarettes per day) in the AlphaTocopherol Beta-Carotene (ATBC) study. Here, we present two additional prospective investigations nested in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial and the Shanghai Women's Health Study (SWHS), and pooled with previously published data from ATBC.
Introduction
Mitochondria are primarily responsible for energy production in eukaryotic cells (1) . Mitochondria have a singular circular mitochondrial DNA molecule. Mitochondria copy number (mtDNA CN) varies to meet energy needs and cope with oxidative stress (2) . Oxidative stress disrupts homeostasis and forms reactive oxygen species leading to DNA damage and genomic instability (3) . In a prospective study among Finnish male smokers, we observed a positive association between mtDNA CN in peripheral blood leukocytes and lung cancer risk (4) .
To replicate the mtDNA CN-lung cancer risk association, nested case-control studies were conducted in two prospective studies, the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial, a population of men and women across the United States, and the Shanghai Women's Health Study (SWHS), a population of mostly nonsmoking Chinese women. These data were then pooled with published data from the Alpha-Tocopherol Beta-Carotene (ATBC) study (4) .
Materials and Methods

Study subjects
The ATBC (5), PLCO (6), and SWHS (7) studies have been described in detail. From ATBC, a total of 229 incident cases with an available blood specimen for analysis were previously identified (4). Controls were matched to cases 1:1 based on date of birth. From PLCO, a total of 442 cases of first primary incident lung cancer with serum at baseline from the screening arm were identified. Controls were matched by age, sex, race, blood collection date, and diagnosing center. From SWHS, 226 incident lung cancer cases with adequate blood for mtDNA analysis were identified, with one control matched to case by age, smoking status, and date of blood collection.
Laboratory analysis
In all three studies, DNA was extracted from peripheral whole blood by the phenol-chloroform method. mtDNA CN was assayed in the same laboratory by qPCR using the ratio of the estimated threshold cycle number of ND1 mitochondrial gene and the B-globin nuclear gene, HBB (8) . The coefficient of variation for PLCO, SWHS, and ATBC was 14%, 7%, and 13%, respectively. After excluding bad runs, poor-quality DNA, or subjects with missing demographic variables, 227 cases and 227 controls in ATBC, 426 cases and 436 controls in PLCO, and 221 cases and 222 controls in SWHS were included in the final analysis.
Statistical analysis
Differences between cases and controls for demographic characteristics were tested with the Wilcoxon-signed rank-sum test for continuous variables and the Pearson c 
Results
Selected demographic characteristics of the study population are described in Table 1 . Statistically significant differences between cases and controls in BMI and years of smoking were observed in the ATBC and PLCO populations but not in SWHS. Age, sex, race (all Caucasian in ATBC, Asian in SWHS), and mtDNA CN levels were not different between cases and controls across the three populations.
mtDNA CN was not associated with lung cancer risk in the PLCO or SWHS data; pooled analysis was also null with evidence of heterogeneity across studies (P heterogeneity ¼ 0.0001; Table 2 ). mtDNA CN and lung cancer risk associations were inverse in male smokers in PLCO, the opposite direction of ATBC. Similarly, comparing heavy smokers to non/light smokers, associations in PLCO were the opposite direction of ATBC (data not shown). No differential associations were observed by histology or follow-up time (data not shown).
Discussion
The mtDNA CN and lung cancer risk association observed in ATBC did not replicate in PLCO, SWHS, and pooled study populations. There was no consistent evidence of an association across populations by sex or smoking status/intensity. This pooled study suggests no consistent association between prediagnostic mtDNA CN levels and lung cancer risk across several populations.
Our study included diverse study populations. Additional strengths included the combined large sample size and the standardized specimen processing and mtDNA CN assay across the three studies. The primary weakness of this study was the single measurement of mtDNA CN. Copy number could change over time, and this study was unable to determine intrapersonal variation over time.
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